![share_log](https://pubimg.futunn.com/2020121102869270fd01c102176.jpg?imageMogr2/thumbnail/76x76!/ignore-error/1/format/webp)
Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
Vivos Therapeutics | 8-K: Current report
Vivos Therapeutics | 8-K:重大事件
牛牛AI助理已提取核心訊息
On March 28, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The company reported a decrease in revenue to $3.2 million for the fourth quarter and $13.8 million for the full year, compared to the previous year's figures of $4.0 million and $16.0 million, respectively. This decline was attributed to lower appliance revenue and enrollments in the Vivos Integrated Provider program, partially offset by increased revenue from home sleep testing services and seminars. Despite the revenue drop, Vivos achieved a 27% reduction in annual operating expenses due to cost-cutting initiatives, leading to a significant reduction in net loss for both the fourth quarter and...Show More
On March 28, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The company reported a decrease in revenue to $3.2 million for the fourth quarter and $13.8 million for the full year, compared to the previous year's figures of $4.0 million and $16.0 million, respectively. This decline was attributed to lower appliance revenue and enrollments in the Vivos Integrated Provider program, partially offset by increased revenue from home sleep testing services and seminars. Despite the revenue drop, Vivos achieved a 27% reduction in annual operating expenses due to cost-cutting initiatives, leading to a significant reduction in net loss for both the fourth quarter and the full year. The company also highlighted the successful exercise of a common stock purchase warrant in February 2024, which generated approximately $4.0 million in gross proceeds. Vivos reported treating over 42,000 patients with its patented oral appliances and training over 1,900 dentists in The Vivos Method. Strategic agreements with Ormco and On Demand Orthodontist were announced to expand product lines and create additional revenue opportunities. Vivos also entered into an exclusive distribution agreement with NOUM DMCC for the MENA region and announced a clinical trial at Stanford Medicine to test its DNA appliance. A reverse stock split was effected in October 2023, and an amended distribution agreement with Lincare was signed. Notably, the company received FDA 510(k) clearance for its CARE oral appliances to treat severe obstructive sleep apnea in adults. Vivos anticipates becoming cash flow positive by the end of 2024 if revenue increases as planned.
2024年3月28日,專門治療睡眠相關呼吸障礙的醫療技術公司Vivos Therapeutics, Inc. 公佈了截至2023年12月31日的第四季度和財年的財務業績。該公司報告稱,第四季度的收入下降至320萬美元,全年收入下降至1,380萬美元,而去年同期分別爲400萬美元和1,600萬美元。這一下降歸因於設備收入減少和Vivos綜合提供商計劃的註冊人數減少,但家庭睡眠測試服務和研討會收入的增加部分抵消了這一下降。儘管收入下降,但由於削減成本的舉措,Vivos的年度運營支出減少了27%,從而使第四季度和全年的淨虧損均大幅減少。該公司還強調了2024年2月成功行使普通股購買權證,該認股權證產...展開全部
2024年3月28日,專門治療睡眠相關呼吸障礙的醫療技術公司Vivos Therapeutics, Inc. 公佈了截至2023年12月31日的第四季度和財年的財務業績。該公司報告稱,第四季度的收入下降至320萬美元,全年收入下降至1,380萬美元,而去年同期分別爲400萬美元和1,600萬美元。這一下降歸因於設備收入減少和Vivos綜合提供商計劃的註冊人數減少,但家庭睡眠測試服務和研討會收入的增加部分抵消了這一下降。儘管收入下降,但由於削減成本的舉措,Vivos的年度運營支出減少了27%,從而使第四季度和全年的淨虧損均大幅減少。該公司還強調了2024年2月成功行使普通股購買權證,該認股權證產生了約400萬美元的總收益。Vivos報告說,使用其獲得專利的口腔器械治療了超過42,000名患者,並對1,900多名牙醫進行了Vivos方法培訓。宣佈了與Ormco和On Demand On Demand Othodontist簽訂的戰略協議,以擴大產品線並創造額外的收入機會。Vivos還與NOUM DMCC簽訂了中東和北非地區的獨家分銷協議,並宣佈在斯坦福醫學院進行一項臨床試驗,以測試其DNA設備。反向股票拆分於2023年10月生效,並與Lincare簽署了經修訂的分銷協議。值得注意的是,該公司用於治療成人嚴重阻塞性睡眠呼吸暫停的CARE口腔器械獲得了美國食品藥品管理局510(k)的許可。Vivos預計,如果收入按計劃增加,到2024年底,現金流將變爲正數。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了